Stelliferin Compound Niche Suppression Leukemic Stem Cell Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitumor agents are ineffective against leukemic stem cells that reside in a niche environment, leading to high recurrence rates of leukemia as these cells are resistant to drugs and survive in a resting stage, making it challenging to completely treat malignant tumors.
Innovation Solution
An extract derived from marine organisms, specifically Porifera, containing a Stelliferin compound is isolated and purified, which inhibits the niche formation of leukemic stem cells, enhancing the effectiveness of antitumor agents by targeting and suppressing the niche environment, thereby preventing tumor recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antitumor agents are used to treat leukemia, then the activity and growth of malignant tumor cells are suppressed, but leukemic stem cells survive in a niche environment and cause high recurrence rates
Solution Approach 1:
The invention extracts and targets the niche environment where leukemic stem cells reside by using Stelliferin compounds to suppress niche formation. This separates the treatment approach from directly attacking the stem cells themselves, instead removing their protective habitat, thereby overcoming drug resistance.
Solution Approach 2:
The Stelliferin compound is administered before or alongside conventional antitumor agents to preemptively suppress niche formation. This preliminary action prevents leukemic stem cells from establishing their resistant state, making them vulnerable to subsequent chemotherapy treatments.
2Productivity
If antitumor agents are administered to suppress malignant tumor cell growth, then tumor symptoms are remitted, but leukemic stem cells remain in a resting stage and activate later causing recurrence
Solution Approach 1:
By administering Stelliferin compounds to suppress niche formation before leukemic stem cells can activate and cause recurrence, the invention extends the remission period. This preliminary suppression of niche formation creates a longer window where the disease remains controlled.
Solution Approach 2:
The Stelliferin compound acts as an intermediary that targets the niche environment rather than directly attacking rapidly dividing tumor cells. This indirect approach allows it to affect slow-cycling or resting leukemic stem cells that conventional chemotherapy misses, thereby delaying recurrence.
3Reliability
If a drug targeting niche formation is used in combination with antitumor agents, then complete treatment of leukemia may be achieved, but the complexity of the treatment regimen increases
Solution Approach 1:
The invention combines Stelliferin compounds with conventional antitumor agents into an integrated treatment regimen. This merging of niche suppression therapy with traditional chemotherapy creates a synergistic effect that targets both the niche environment and actively dividing tumor cells, achieving more complete treatment.
Solution Approach 2:
The Stelliferin compound serves multiple functions: it suppresses niche formation, sensitizes leukemic stem cells to chemotherapy, and potentially has direct antiproliferative effects. This multi-functionality allows a single agent to address multiple aspects of the disease, reducing the need for additional specialized treatments.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.